IL-17 and its family members play pivotal roles in shaping the tumor immune microenvironment (TME), influencing tumor progression, immune evasion, and therapeutic responses (Su et al., 2010; Keerthivasan et al., 2014; Qian et al., 2017). This evidence concerns the gene IL17A and neoplasm.